Floatz logo

Mesna

Mantle Cell Lymphoma

Massachusetts General HospitalSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

162 Active assets in the Mantle Cell Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Ruijin Hospital
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BBB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 2BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Busulphan
City of Hope Medical Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Mesna is also rated in:

Hodgkin's LymphomaDormant
BB
Indicative ·
69 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
69 / 100
View asset →
NK/T-cell LymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →